Targeted Therapies in B-Cell Malignancies: ASH 2023 and Beyond - Episode 1

Looking Ahead to Upcoming Presentations at ASH 2023

Expert insights into the evolving treatment landscape for chronic lymphocytic leukemia (CLL), emphasizing upcoming clinical data to be presented at ASH 2023.

Now Viewing
EP. 1: Looking Ahead to Upcoming Presentations at ASH 2023
EP. 2: Targeted Therapy and Role of Biomarkers in B-Cell Malignancies
EP. 3: CLL: Updated Data in the Frontline Setting Presented at ASH 2023
EP. 4: Zanubrutinib Plus Sonrotoclax in Patients With Treatment-Naïve CLL/SLL
EP. 5: Recent Data in Relapsed/Refractory CLL/SLL
EP. 6: Adverse Events for BTK Inhibitors and BCL2 Inhibitors in CLL
EP. 7: Treatment Sequencing for Patients With B-Cell Malignancies
EP. 8: Ongoing Research on Targeted Therapy in Relapsed/Refractory CLL
EP. 9: Future of Treatment of B-Cell Malignancies

This is a video synopsis/summary of an Insights featuring: Nicole Lamanna, MD.

Dr. Nicole Lamanna highlights key data that will be presented at the American Society of Hematology (ASH) 2023 annual meeting about advances in chronic lymphocytic leukemia (CLL) treatment. Several abstracts will provide long-term follow up from phase 3 trials of Bruton tyrosine kinase (BTK) inhibitors, demonstrating their sustained efficacy and safety. Other studies of interest include oral-only combinations of BTK and B-cell lymphoma 2 (BCL2) inhibitors or triplets adding in CD20 monoclonal antibodies. These all oral regimens may match or improve efficacy over historical chemoimmunotherapy. An abstract on BTK inhibitors plus PD1 blockade in Richter’s transformation addresses an area of high unmet need. There will also be updated data on newer agents like BTK degraders for overcoming resistance and noncovalent BTK inhibitors.

Overall, Dr. Lamanna highlights that the wealth of data on practice-changing advances in CLL treatment will be valuable features of ASH 2023.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.